Cardiac responses to drugs at the extremes of age.
Although current knowledge concerning drug responsiveness in the human heart is still deficient at both extremes of age, i.e. in the fetus and the elderly, new information is beginning to emerge. Pharmacodynamic studies have provided a fairly comprehensive picture of the appearance and maturation of the automatic receptors, and also of the emergence and development of sympathetic-adrenergic and parasympathetic-cholinergic mechanisms in the prenatal human heart. A timetable can now be drawn up for the earliest detection of intrinsic responsiveness to numerous adrenergic and cholinergic agonists and antagonists, and to inotropic and antiarrhythmic drugs in the human embryonic and fetal heart. Information on the antenatal cardiac pharmacodynamics of antiarrhythmics and inotropic drugs is mostly confined to some of the classical remedies, so that a systematic study of the effects of the various newer drugs is warranted. As legal abortions yield prenatal hearts only in very limited numbers, human embryonic and fetal cardiac tissue and cell cultures could also be used for such research under both physiological and pathological conditions, such as hypoxia or simulated ischemia. Since the sporadic data available on the transplacental efficacy of maternally administered cardioactive agents are encouraging, extensive clinical investigation into the pharmacological control of intrauterine cardiac arrhythmias and heart failure, based on new, high-resolution fetal echocardiographic techniques to monitor the success of drug therapy at the various stages of prenatal development, is also a stimulating challenge. In the elderly human heart, pharmacodynamically-based alterations in responsiveness to drugs have so far been conclusively proven for adrenergic agents.(ABSTRACT TRUNCATED AT 250 WORDS)
Papp
J G
JG
Department of Pharmacology, Albert Szent-Györgyi Medical University, Szeged, Hungary.
D000322:Adrenergic Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D012898:Autacoids / Q000494:pharmacology; D002301:Cardiac Glycosides / Q000494:pharmacology; D002316:Cardiotonic Agents / Q000494:pharmacology; D005318:Fetal Heart / Q000187:drug effects* / Q000502:physiology; D006321:Heart / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D010277:Parasympathomimetics / Q000494:pharmacology*; D011941:Receptors, Adrenergic / Q000502:physiology
D000322:Adrenergic Agonists; D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D012898:Autacoids; D002301:Cardiac Glycosides; D002316:Cardiotonic Agents; D010277:Parasympathomimetics; D011941:Receptors, Adrenergic